相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
LBA31A PHASE IB STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH HUMAN PAPIILLOMA VIRUS (HPV)-POSITIVE AND NEGATIVE HEAD AND NECK CANCER (HNC)
L.Q. Chow et al.
ANNALS OF ONCOLOGY (2017)
Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
Robert I. Haddad et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
M. Kowanetz et al.
ANNALS OF ONCOLOGY (2016)
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
Marisa Dolled-Filhart et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue
Marisa Dolled-Filhart et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Emerging targeted therapies for melanoma
Douglas B. Johnson et al.
EXPERT OPINION ON EMERGING DRUGS (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Chunwan Lu et al.
ONCOIMMUNOLOGY (2016)
deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution
Rachel Rosenthal et al.
GENOME BIOLOGY (2016)
The Ensembl Variant Effect Predictor
William McLaren et al.
GENOME BIOLOGY (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors
Martha R. Neagu et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data
F. Favero et al.
ANNALS OF ONCOLOGY (2015)
OptiType: precision HLA typing from next-generation sequencing data
Andras Szolek et al.
BIOINFORMATICS (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Microsatellite Instability Detection by Next Generation Sequencing
Stephen J. Salipante et al.
CLINICAL CHEMISTRY (2014)
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes
Ludmil B. Alexandrov et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2014)
Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer
Ulka Vaishampayan
CURRENT OPINION IN ONCOLOGY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
PyClone: statistical inference of clonal population structure in cancer
Andrew Roth et al.
NATURE METHODS (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Jerome Galon et al.
IMMUNITY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Daniel C. Koboldt et al.
GENOME RESEARCH (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling
Domenico Coppola et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
Aaron McKenna et al.
GENOME RESEARCH (2010)
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2010)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
HLA class I supertypes: a revised and updated classification
John Sidney et al.
BMC IMMUNOLOGY (2008)
Epitope landscape in breast and colorectal cancer
Neil H. Segal et al.
CANCER RESEARCH (2008)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients
HY Dai et al.
CANCER RESEARCH (2005)
Definition of supertypes for HLA molecules using clustering of specificity matrices
O Lund et al.
IMMUNOGENETICS (2004)
Reliable prediction of T-cell epitopes using neural networks with novel sequence representations
M Nielsen et al.
PROTEIN SCIENCE (2003)
分享论文
